![]() |
SRRK | Scholar Rock Holding Corp |
Biological Products (no Diagnostic Substances) |
Book value per $ invested | $ 0.14 |
Leverage | 22.38% |
Market Cap | $ 2.7B |
PE | 0.00 |
Dividend Yield | 0.00% |
Profit | $ -244.8m |
Margin | -4297.50% |
Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.